Activities of Clare DALY related to 2021/2013(INI)
Plenary speeches (1)
A pharmaceutical strategy for Europe (debate)
Amendments (16)
Amendment 37 #
Motion for a resolution
Recital A
Recital A
A. whereas health is fundamental to the well-being of Europeansall and equitable access to healthcare is a pillar of the EU; whereas safe, affordable medicines are needed to combat all diseases; whereas patients should be at the centre of all health policies, alongsidend investment and research should be patient-centred;
Amendment 48 #
Motion for a resolution
Recital B
Recital B
B. whereas COVID-19 has had an huge impact on people’s health, physical and mental, and on the economy; whereas it has highlighted both the EU’s strengths and weaknesses; whereas in order to strengthen the resilience of our national health systems to cross-border threats, more European integration is necessary; whereas a European Health Union, which contributes to an increasingly social Una certain level of European integration, is key in this pronecessary;
Amendment 137 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Stresses that public investment in research into and the development of innovative medicines and treatments, as well as ensuring access to safe, effective and high-quality medicines, are essential for making progress in the prevention and treatment of diseases;
Amendment 166 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Considers that public investment in research has not been sufficient to meet the therapeutic needs of patients, particularly patients with rare diseases, paediatric cancers and neurodegenerative diseases, or to deal with antimicrobial resistance (AMR);
Amendment 255 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5 a. Stresses that affordable medicines can be best guaranteed through public R&D coupled with public production of medicines, and urges Member States to invest accordingly;
Amendment 274 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Calls on the Commission to review the incentive system, increase price transparency, highlight the causes limiting affordability and patient access to medicinal products, and propose sustainable solutions that also promote competition;
Amendment 299 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Stresses that generic and biosimilar medicines are accessible and affordable treatments and contribute greatly to the budgetary sustainability of healthcare systems; calls on the Commission to introduce measures to support a greater market presence of these medicines and to harmonise at EU level the interpretation of the so-called Bolar provision concerning possible exemptions from the legal framework for the Unitary Patent system for generic drug manufacturers; further calls on the Commission to design rules for the industry that promote research, development and the production of generic and biosimilar medicines in the EU and to propose EU protocols for the interchangeability of biosimilar medicines; calls for the removal of barriers to the production and distribution of generic medicines; calls on Member States to increase public production of generic and biosimilar medicines;
Amendment 337 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Highlights the benefits ofproblems related to public- private partnership tenders for national health systems in funding research into and the production of innovative medicines, such as concentration of research and development in profitable medicinal areas; underscores how this model has contributed to the neglect of rare diseases in particular;
Amendment 385 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Is concerned that the affordability of medicines remains a challenge for national health systems, and that innovative medicines are expensive; welcomes the Commission’s intention to review pharmaceutical legislation to promote robust competition and to stabilise and balance national drug pricing systems; strongly believes that the pricing of medicines should not be left to fluctuations in the market;
Amendment 409 #
Motion for a resolution
Subheading 2
Subheading 2
Supporting a competitive and innovativen EU pharmaceutical industry that meets peoples' needs
Amendment 413 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Insists that a focus on competitiveness for the EU pharmaceutical industry is strategic and more responsive tocontrary to meeting patients’ needs; points out that the industry needs a stable, flexible and agile regulatory environto be regulated to ensure patients' needs are ment; believes that it can thrive globally with a clear, robust and efficient intellectual property system; welcomes the initiative to build interoperable digital infrastructure for the European Health Data Spacthe industry can provide an essential public good by providing medicines to people in need rather than profits to patent-holders; recalls the contribution to global public health from the act of avoiding the intellectual properly system, such as with the development of the highly-successful polio vaccine;
Amendment 491 #
Motion for a resolution
Paragraph 13
Paragraph 13
Amendment 523 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Highlights the fact that gene and cell therapies, personalised medicine, nanotechnology, next-generation vaccines, e-health and the ‘Million plus genomes’ initiative can bring enormous benefits in relation to the prevention, diagnosis, treatment and post-treatment of all diseases; urges the Commission to develop the appropriate regulatory frameworks, to guidregulate new business models, and to run information campaigns to raise awareness and encouragsure the usptake of these innovations;
Amendment 591 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Recalls that the EU’s odepen strategic autonomy is linked todence on the constant and sufficient availability of medicines in all Member States; calls on the Commission to develop an early warning system for drug shortages, based on a European information network on supply problems, to increase public-private collaboration and to monitor the obligation on the part of industry to provide early and transparent information on the availability of medicines; calls on the Commission to develop a mechanism to safeguard transparency in production and supply chains in the event of emergencies;
Amendment 702 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Calls on the Commission to further facilitate access to global markets for the EU pharmaceutical industry, including small and medium-sized enterprises, through a level playing field and a regulatory framework facilitating trade agreements that prize innovation-based competitivenesare based on peoples' needs, in order to make the pharmaceutical sector a strategic pillaand public sector of the EU;
Amendment 713 #
Motion for a resolution
Paragraph 23 a (new)
Paragraph 23 a (new)
23 a. Believes the EU Member States have a responsibility to ensure equitable access to medicines and therapeutics worldwide; calls on the EU to advocate access to medicines globally, and to commit to ensuring that none of its actions block access to medicines and therapeutic care, including in the WTO;